Tagged with strategy

Ireland Barry Joyce, MD at VWR Ireland, takes us through the priorities of the first few months of his appointment, the strategic position of VWR in Ireland and within the global VWR (NASDAQ: VWR) organization, the importance of taking a partnership approach with clients instead of a transactional one, and his…

Ireland The strong flow of FDI into Ireland has led to a vibrant ecosystem of Irish service providers, who have grown up servicing the needs of pharma MNCs. Working for FDI clients has put Irish companies to the test and pushed them to work to the highest standards. “Top global pharma…

Mexico Ricardo Amtmann, President at Laboratorios Sanfer, explains how they have grown their business by 100 percent throughout the last three years and showcases the added value of Sanfer to patients in Mexico and internationally by offering high quality drugs and boosting the sales of in-licensed medicines. Could you introduce yourself…

Singapore Christopher Snook discusses his dual role as Head of Group Country Management as well as Country President for Singapore, highlighting the importance of adhering to in-house as well as country-specific regulatory frameworks and the continued importance of Singapore to the global group.   We will continue to see Singapore in…

Switzerland Frederic Bengold, MD of Servier Switzerland, on the affiliate’s main growth drivers, an exciting collaboration with Novartis on heart failure medication, and the intricacies of market access in Switzerland. Could you please start by introducing Servier’s Swiss affiliate? We enjoy a longstanding presence and reputation in Switzerland. The local affiliate…

Switzerland The CEO of Max Zeller, a Swiss Phytopharmaceutical company, highlights the immense benefits his products have and furthermore discusses the company’s internationalization strategy. Mr Boonen, you joined Max Zeller in June 1999 and have spent almost all your professional career here. How have you seen the company evolve over time…

Switzerland Santen’s Head of EMEA explains why the company established their new regional headquarters in Geneva, Switzerland and highlights the three key strategic pillars on which he bases the growth strategy for the region.   The immense talent present here contributes to the strategic value of the EMEA region, which we…

Mexico Patricia López, general manager at seca Mexico, showcases the added value of seca’s product portfolio and explains that interconnectivity should be medical devices’ path of development; generating benefits for patients, physicians and government. Could you please update our international readers on the operations of seca in Mexico? “Latin America has…

Switzerland The Chairman of Ferring’s Group Operating Committee and Senior Vice President Europe-Canada elaborates on how Europe can be the thinking engine for global pharmaceutical trends.   Ferring has bundled the European and Canadian markets into one single region. Could you please introduce us to the full scope of your role…

Taiwan Grace Yeh, Founder, President, and CEO of PharmaEngine, one of the most eye-catching success stories to recently emerge from Taiwan’s maturing biopharmaceutical sector, documents the main success factors that have allowed PharmaEngine to become the first Taiwan-based company to receive FDA approval for a locally-developed oncology treatment, as well as…

Ireland James Lennertz, Group VP and GM EUMEA for BioMarin, discusses the key highlights of the past few years for BioMarin, their unique positioning as a company offering innovative therapies for ultra-rare diseases, the main challenge he sees for BioMarin’s international operations, and his priorities for the next few years. James,…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…